Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550355 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00550355 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 78 participants.
The verdict
NCT00550355, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD 0360324 in patients with rheumatoid arthritis receiving methotrexate.
Interventions
- DRUG Placebo
- DRUG PD 0360324
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550355
The ClinicalTrials.gov registry entry for NCT00550355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00550355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550355 about?
NCT00550355 is a clinical study titled "Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis". This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD 0360324 in patients with rheumatoid arthritis receiving methotrexate.
What is the current status of trial NCT00550355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2007-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00550355?
The interventions under investigation include: Placebo (DRUG), PD 0360324 (DRUG).
Who is sponsoring clinical trial NCT00550355?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.